• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前细胞学检查对甲状腺髓样癌的局限性:为优化初始甲状腺髓样癌特异性手术提出的改进术前诊断建议。

Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery.

机构信息

Division of Thyroid and Parathyroid Surgery, Department of Otolaryngology, Massachusetts Eye and Ear and Harvard Medical School, Boston, Massachusetts, USA.

Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Head Neck. 2021 Mar;43(3):920-927. doi: 10.1002/hed.26550. Epub 2020 Dec 2.

DOI:10.1002/hed.26550
PMID:33269526
Abstract

BACKGROUND

Preoperative diagnosis of medullary thyroid carcinoma (MTC) is often difficult, given the poor sensitivity of fine-needle aspiration (FNA) cytology for MTC. This study investigates this issue and presents recommendations for improving preoperative diagnostic paradigms in MTC cases.

DESIGN/METHOD: Histopathologically confirmed MTC patients with preoperative cytologic assessment of index nodules were enrolled. FNA diagnosis, final pathology, and surgery details were collected.

RESULTS

Out of 71 patients, 49 (69%) were diagnosed by FNA as either definitive MTC (35, 49%) or suspected MTC (14, 20%) and 22 (31%) patients had no indication of MTC on FNA.

CONCLUSION

In a tertiary-care setting, one-third of subjects had an FNA interpretation that did not suggest the possibility of MTC. The limitations of preoperative diagnosis are especially problematic for MTC as they can cause delayed or incomplete treatment. Additional testing is proposed to improve preoperative diagnosis and surgical care of MTC patients.

摘要

背景

由于细针穿刺细胞学检查(FNA)对甲状腺髓样癌(MTC)的敏感性较差,因此术前诊断 MTC 往往较为困难。本研究探讨了这一问题,并提出了改善 MTC 患者术前诊断模式的建议。

设计/方法:入组了经组织病理学证实的 MTC 患者,这些患者在术前对索引结节进行了细胞学评估。收集了 FNA 诊断、最终病理和手术细节。

结果

71 例患者中,49 例(69%)经 FNA 诊断为明确的 MTC(35 例,49%)或疑似 MTC(14 例,20%),22 例(31%)患者的 FNA 未提示 MTC。

结论

在三级保健机构中,三分之一的患者的 FNA 检查结果不提示 MTC 的可能性。术前诊断的局限性对 MTC 尤其成问题,因为它们可能导致治疗延迟或不彻底。建议进行额外的检测以改善 MTC 患者的术前诊断和手术护理。

相似文献

1
Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery.术前细胞学检查对甲状腺髓样癌的局限性:为优化初始甲状腺髓样癌特异性手术提出的改进术前诊断建议。
Head Neck. 2021 Mar;43(3):920-927. doi: 10.1002/hed.26550. Epub 2020 Dec 2.
2
Cytologic diagnosis of medullary thyroid carcinoma in the Asia-Pacific region.亚太地区甲状腺髓样癌的细胞学诊断。
Diagn Cytopathol. 2021 Jan;49(1):60-69. doi: 10.1002/dc.24586. Epub 2020 Aug 22.
3
Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma.优化细针穿刺活检降钙素测量在检测甲状腺髓样癌中的诊断准确性。
Thyroid. 2024 Feb;34(2):186-196. doi: 10.1089/thy.2023.0313. Epub 2024 Jan 12.
4
Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: A case report and review of the literatures.血清降钙素阴性的混合性髓样-滤泡状癌,最初经细针穿刺细胞学检查诊断为甲状腺髓样癌:一例报告并文献复习
Diagn Cytopathol. 2018 Aug;46(8):690-693. doi: 10.1002/dc.23924. Epub 2018 Mar 10.
5
Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.甲状腺髓样癌的细针穿刺细胞学检查:日本单机构经验
Endocr J. 2017 Nov 29;64(11):1099-1104. doi: 10.1507/endocrj.EJ17-0238. Epub 2017 Sep 5.
6
An old friend, a new insight: Calcitonin measurement in serum and aspiration needle washout fluids significantly increases the early and accurate detection of medullary thyroid cancer.一位老朋友,新的见解:血清降钙素测量和抽吸针洗脱液显著提高了甲状腺髓样癌的早期和准确检测。
Cancer Cytopathol. 2024 Mar;132(3):161-168. doi: 10.1002/cncy.22779. Epub 2023 Nov 10.
7
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.术前识别甲状腺髓样癌(MTC): Afirma MTC RNA 测序分类器的临床验证。
Thyroid. 2022 Sep;32(9):1069-1076. doi: 10.1089/thy.2022.0189. Epub 2022 Aug 8.
8
Calcitonin levels in washout samples vs. cytology in the detection of malignant lymph node metastasis in recurrent medullary thyroid cancer.降钙素水平在洗脱样本与细胞学检查在复发性甲状腺髓样癌中恶性淋巴结转移的检测。
Turk J Med Sci. 2021 Dec 13;51(6):3061-3066. doi: 10.3906/sag-2105-280.
9
Usefulness of Serum Calcitonin in Patients Without a Suspicious History of Medullary Thyroid Carcinoma and with Thyroid Nodules Without an Indication for Fine-Needle Aspiration or with Benign Cytology.血清降钙素在无甲状腺髓样癌可疑病史、甲状腺结节无细针穿刺指征或细胞病理学检查为良性的患者中的应用价值
Horm Metab Res. 2016 Jun;48(6):372-276. doi: 10.1055/s-0042-107246. Epub 2016 May 20.
10
Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.用国际甲状腺髓样癌分级系统对细针抽吸细胞学标本进行甲状腺髓样癌分级:细胞学-组织学相关性。
Cancer Cytopathol. 2024 Apr;132(4):224-232. doi: 10.1002/cncy.22778. Epub 2023 Dec 8.

引用本文的文献

1
Combining Procalcitonin and Calcitonin for the Diagnosis of Medullary Thyroid Cancer: A Two-Step Approach.联合降钙素原与降钙素用于诊断甲状腺髓样癌:一种两步法。
Clin Endocrinol (Oxf). 2025 Oct;103(4):587-595. doi: 10.1111/cen.15287. Epub 2025 Jun 4.
2
The diagnostic challenges of medullary thyroid carcinoma: A practical guide for cytopathologists.甲状腺髓样癌的诊断挑战:细胞病理学家实用指南。
Cancer Cytopathol. 2025 Jun;133(6):e70023. doi: 10.1002/cncy.70023.
3
Role of the calcium stimulation test in diagnosing medullary thyroid cancer: is it adequate to achieve a diagnosis in both sexes? An individual patient data meta-analysis.
钙刺激试验在诊断甲状腺髓样癌中的作用:对两性进行诊断是否足够?一项个体患者数据荟萃分析。
Eur Thyroid J. 2025 May 29;14(3). doi: 10.1530/ETJ-24-0347. Print 2025 Jun 1.
4
Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.甲状腺髓样癌的流行病学、临床表现及诊断
Recent Results Cancer Res. 2025;223:93-127. doi: 10.1007/978-3-031-80396-3_4.
5
Overview of management and therapeutic advances in medullary thyroid cancer.甲状腺髓样癌的管理与治疗进展概述
Endocr Oncol. 2025 Mar 11;5(1):e240077. doi: 10.1530/EO-24-0077. eCollection 2025 Jan.
6
Medullary Thyroid Carcinoma Detected by Routine Health Screening Had Better Clinical Outcome and Survival.通过常规健康筛查发现的甲状腺髓样癌具有更好的临床结局和生存率。
Endocrinol Metab (Seoul). 2025 Jun;40(3):414-420. doi: 10.3803/EnM.2024.2214. Epub 2025 Mar 5.
7
Medullary Thyroid Carcinoma in the Background of Non-neoplastic Toxic Nodular Goiter.非肿瘤性毒性结节性甲状腺肿背景下的甲状腺髓样癌
AACE Clin Case Rep. 2024 Sep 2;10(6):249-252. doi: 10.1016/j.aace.2024.08.008. eCollection 2024 Nov-Dec.
8
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.分子遗传学、治疗学和 RET 抑制剂耐药性在甲状腺髓样癌中的应用及未来展望。
Cell Commun Signal. 2024 Sep 28;22(1):460. doi: 10.1186/s12964-024-01837-x.
9
New Opportunities for Preoperative Diagnosis of Medullary Thyroid Carcinoma.甲状腺髓样癌术前诊断的新机遇
Biomedicines. 2023 May 18;11(5):1473. doi: 10.3390/biomedicines11051473.
10
Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.50734 例 Bethesda III-VI 级甲状腺结节的 ThyroSeq v3 分子谱分析:对个体化管理的启示。
J Clin Endocrinol Metab. 2023 Oct 18;108(11):2999-3008. doi: 10.1210/clinem/dgad220.